Exact Sciences Corp. [EXAS] stock is trading at $59.44, up 3.32%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The EXAS shares have gain 3.32% over the last week, with a monthly amount drifted -9.11%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Exact Sciences to Participate in March Investor Conference. In a post published today on Yahoo Finance, Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
From an analyst’s perspective:
Exact Sciences Corp. [NASDAQ: EXAS] stock has seen the most recent analyst activity on January 02, 2024, when The Benchmark Company upgraded its rating to a Buy but kept the price target unchanged to $91 for it. Previously, Guggenheim started tracking the stock with Buy rating on December 14, 2023, and set its price target to $90. On December 13, 2023, Wolfe Research initiated with a Outperform rating and assigned a price target of $95 on the stock. Piper Sandler upgraded its rating to a Overweight but stick to its price target of $90 on October 10, 2023. Bernstein initiated its recommendation with a Outperform and recommended $83 as its price target on September 28, 2023. The Benchmark Company downgraded its rating to Hold for this stock on August 02, 2023. In a note dated May 10, 2023, Craig Hallum upgraded an Buy rating on this stock and boosted its target price from $55 to $85.
Exact Sciences Corp. [EXAS] stock has fluctuated between $56.05 and $100.77 over the past year. Currently, Wall Street analysts expect the stock to reach $106.29 within the next 12 months. Exact Sciences Corp. [NASDAQ: EXAS] shares were valued at $59.44 at the most recent close of the market. An investor can expect a potential return of 78.82% based on the average EXAS price forecast.
Analyzing the EXAS fundamentals
Exact Sciences Corp. [NASDAQ:EXAS] reported sales of 2.50B for the trailing twelve months, which represents a growth of 16.98%. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.08%, and Net Profit Margin reading is -0.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.07 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 57.53 points at the first support level, and at 55.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 60.96, and for the 2nd resistance point, it is at 62.47.
Exact Sciences Corp. [EXAS] reported earnings per share of -$0.27 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.46/share, meaning a difference of $0.19 and a surprise factor of 41.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0 per share as compared to estimates of -$0.48 per share, a difference of $0.48 representing a surprise of 100.00%.
Ratios To Look Out For
For context, Exact Sciences Corp.’s Current Ratio is 2.32. Also, the Quick Ratio is 2.07, while the Cash Ratio stands at 1.18. Considering the valuation of this stock, the price to sales ratio is 4.32, the price to book ratio is 3.43.
Transactions by insiders
Recent insider trading involved Conroy Kevin T, President and CEO, that happened on Feb 27 when 6263.0 shares were sold. Chief Commercial Officer, Cunningham Everett completed a deal on Feb 27 to sell 3648.0 shares. Meanwhile, Chief Financial Officer Elliott Jeffrey Thomas sold 2710.0 shares on Feb 27.
